Empadiance-M 5/1000 is an oral combination tablet containing **Empagliflozin (an SGLT2 inhibitor)** and **Metformin (a biguanide)**, produced by Alhavi Pharmaceutical.
It is used to manage blood glucose levels in adults with type 2 diabetes mellitus.
The complementary mechanisms of these two active ingredients provide enhanced glycemic control — Empagliflozin promotes urinary glucose excretion, while Metformin decreases hepatic glucose production and improves insulin sensitivity.
Empadiance-M is available in two strengths: **5/1000 mg** and **12.5/1000 mg** tablets.
Empadiance-M 5/1000 (Empagliflozin + Metformin)
Dosage form: Tablet
Empadiance-M is indicated for:
• Control of blood glucose levels in adults with type 2 diabetes mellitus requiring combination therapy with Empagliflozin and Metformin
• Can be used as an adjunct to diet and exercise, alone or in combination with other antidiabetic agents
This dual-action formula enhances glycemic control by combining insulin-sensitizing and glucose-excreting mechanisms.
• Recommended dose: **5/1000 mg twice daily**
• Take **with or after meals** to reduce gastrointestinal side effects associated with Metformin
• Swallow tablets whole with water — do not crush or chew
• Continue dietary and exercise recommendations as prescribed by your physician
• Use under medical supervision with regular monitoring of blood glucose and kidney function